XM n’offre pas ses services aux résidents des États-Unis d’Amérique.
O
O

OpkoHealth


Actualités

U.S. STOCKS Meta Platforms, Cintas, Toast

BUZZ-U.S. STOCKS ON THE MOVE-Meta Platforms, Cintas, Toast Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq and the S&P 500 bounced back on Thursday, boosted by a recovery in megacaps, as an upbeat forecast from Taiwan Semiconductor Manufacturing lifted chip stocks after a sharp sell-off in the previous session.
A
B
C
F
I
M
M
N
N
O
A
U
U
U
E
M
T

Opko Health climbs on stock buyback plan

BUZZ-Opko Health climbs on stock buyback plan ** Shares of Opko Health OPK.O up 8.4% premarket to $1.54, highest since beginning of 2024, as biopharma and diagnostics firm plans to buy back stock ** Co announces $100 mln share repurchase program expected to be funded from existing cash and future cash flows ** With ~697 mln shares outstanding, co has ~$990 mln market cap as of Weds ** “We believe OPKO’s shares are significantly undervalued and offer an attractive investment opportunity.
O

OPKO Health Announces $100 Million Share Repurchase Program

BRIEF-OPKO Health Announces $100 Million Share Repurchase Program July 18 (Reuters) - OPKO Health Inc OPK.O : OPKO HEALTH ANNOUNCES $100 MILLION SHARE REPURCHASE PROGRAM OPKO HEALTH INC - EXPECTS TO FUND REPURCHASE PROGRAM FROM EXISTING CASH AND CASH EQUIVALENTS, AND FUTURE CASH FLOWS Source text for Eikon: ID:nGNXKb9Qb Further company coverage: OP
O

U.S. Elevance Health, J&J, Primerica

U.S. RESEARCH ROUNDUP-Elevance Health, J&J, Primerica July 18 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Elevance Health, J&J and Primerica, on Thursday. HIGHLIGHTS * Elevance Health Inc ELV.N : Leerink Partners cuts target price to $620 from $630 * J&J JNJ.N : TD Cowen cuts target price to $185 from $195 * Primerica Inc PRI.N : Jefferies raises target price to $249 from $239 * Travelers Companies Inc TRV.N : HS
A
A
O
P
Q
A
A
C

Weight-loss drug developers line up to tap market worth $150 billion

FACTBOX-Weight-loss drug developers line up to tap market worth $150 billion Updates with latest details on Pfizer, Roche and Carmot Therapeutics July 17 (Reuters) - Novo Nordisk's NOVOb.CO Wegovy and Eli Lilly's LLY.N Zepbound are so far the leaders in the weight-loss drug market, which is estimated to be worth about $150 billion by the early 2030s.
A
O
P
R

Weight-loss drug developers line up to tap market worth $150 billion

FACTBOX-Weight-loss drug developers line up to tap market worth $150 billion Updates estimate for obesity drug market size June 4 (Reuters) - Novo Nordisk's NOVOb.CO Wegovy and Eli Lilly's LLY.N Zepbound are so far the leaders in the weight-loss drug market, which is estimated to be worth about $150 billion by the e arly 2030s . But there are several other drug developers aiming to join the bandwagon.
A
O
P
R

Weight-loss drug developers line up to tap market worth $150 billion

FACTBOX-Weight-loss drug developers line up to tap market worth $150 billion Updates estimate for obesity drug market size June 4 (Reuters) - Novo Nordisk's NOVOb.CO Wegovy and Eli Lilly's LLY.N Zepbound are so far the leaders in the weight-loss drug market, which is estimated to be worth about $150 billion by the e arly 2030s . But there are several other drug developers aiming to join the bandwagon.
A
O
P
R

OPKO Health Inc reports results for the quarter ended in March - Earnings Summary

OPKO Health Inc reports results for the quarter ended in March - Earnings Summary OPKO Health Inc OPK.OQ reported a quarterly adjusted loss of 12 cents​​ per share for the quarter ended in March, lower than the same quarter last year, when the company reported EPS of -2 cents. The mean expectation of six analysts for the quarter was for a loss of 9 cents per share.
O

OPKO Health Q1 Net Income 81.8 Million

BRIEF-OPKO Health Q1 Net Income USD -81.8 Million May 07 (Reuters) - OPKO Health Q1 revenue from services USD 126.9 million. Q1 operating income USD -71.5 million Q1 pretax profit USD -83.2 million Q1 basic EPS USD -0.12 vs. IBES estimate USD -0.1
O

OPKO Health Inc <OPK.OQ> expected to post a loss of 9 cents a share - Earnings Preview

OPKO Health Inc expected to post a loss of 9 cents a share - Earnings Preview OPKO Health Inc OPK.OQ OPK.O is expected to show a fall in quarterly revenue when it reports results on May 7 for the period ending March 31 2024 The Miami Florida-based company is expected to report a 23.0% decrease in revenue to $182.99 million from $237.6 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.The company's guidance on February 27 2024, for the period ended March 31,
O

OPKO Health Inc <OPK.OQ> expected to post a loss of 9 cents a share - Earnings Preview

OPKO Health Inc expected to post a loss of 9 cents a share - Earnings Preview OPKO Health Inc OPK.OQ OPK.O is expected to show a fall in quarterly revenue when it reports results on May 1 (estimated) for the period ending March 31 2024 The Miami Florida-based company is expected to report a 23.0% decrease in revenue to $182.99 million from $237.6 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.The company's guidance on February 27 2024, for the period end
O



Conditions

Actifs populaires

Avertissement : Les entités de XM Group proposent à notre plateforme de trading en ligne un service d'exécution uniquement, autorisant une personne à consulter et/ou à utiliser le contenu disponible sur ou via le site internet, qui n'a pas pour but de modifier ou d'élargir cette situation. De tels accès et utilisation sont toujours soumis aux : (i) Conditions générales ; (ii) Avertissements sur les risques et (iii) Avertissement complet. Un tel contenu n'est par conséquent fourni que pour information générale. En particulier, sachez que les contenus de notre plateforme de trading en ligne ne sont ni une sollicitation ni une offre de participation à toute transaction sur les marchés financiers. Le trading sur les marchés financiers implique un niveau significatif de risques pour votre capital.

Tout le matériel publié dans notre Centre de trading en ligne est destiné à des fins de formation / d'information uniquement et ne contient pas – et ne doit pas être considéré comme contenant – des conseils et recommandations en matière de finance, de fiscalité des investissements ou de trading, ou un enregistrement de nos prix de trading ou une offre, une sollicitation, une transaction à propos de tout instrument financier ou bien des promotions financières non sollicitées à votre égard.

Tout contenu tiers, de même que le contenu préparé par XM, tels que les opinions, actualités, études, analyses, prix, autres informations ou liens vers des sites tiers contenus sur ce site internet sont fournis "tels quels", comme commentaires généraux sur le marché et ne constituent pas des conseils en investissement. Dans la mesure où tout contenu est considéré comme de la recherche en investissement, vous devez noter et accepter que le contenu n'a pas été conçu ni préparé conformément aux exigences légales visant à promouvoir l'indépendance de la recherche en investissement et, en tant que tel, il serait considéré comme une communication marketing selon les lois et réglementations applicables. Veuillez vous assurer que vous avez lu et compris notre Avis sur la recherche en investissement non indépendante et notre avertissement sur les risques concernant les informations susdites, qui peuvent consultés ici.

Avertissement sur les risques : votre capital est à risque. Les produits à effet de levier ne sont pas recommandés pour tous. Veuillez consulter notre Divulgation des risques